Pharma: Other News To Note
The European Medicines Agency accepted submission of a marketing authorization application for aripiprazole depot formulation by Otsuka Pharmaceutical Co. Ltd., of Tokyo, and H. Lundbeck A/S, of Copenhagen. The application is for once-monthly injection for maintenance treatment of adults with schizophrenia. It is designed for relapse prevention.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.